CoraLite® Plus 488 Anti-Mouse CD25/IL-2RA (PC61.5)

CD25/IL-2RA Monoclonal Antibody for FC
Cat No. CL488-65137

产品说明书

CloneNo. PC61.5

宿主/亚型

Rat / IgG1, lambda

种属反应性

mouse

应用

FC

CD25, Il-2ra, Il2ra, IL-2R subunit alpha, Il2r

缓冲液配方:  PBS and Azide
PBS and Azide
规格: 

-/ -


经过测试的应用

Positive FC detected inmouse splenocytes
For other applications, we recommend the unconjugated version of this antibody, 65137-1-Ig

推荐稀释比

应用推荐稀释比
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

产品信息

CL488-65137 targets CD25/IL-2RA in FC applications and shows reactivity with mouse samples.

经测试应用 FC Application Description
经测试反应性 mouse
免疫原 N/A 种属同源性预测
宿主/亚型 Rat / IgG1, lambda
抗体类别 Monoclonal
产品类型 Antibody
全称 interleukin 2 receptor, alpha chain
别名 CD25, Il-2ra, Il2ra, IL-2R subunit alpha, Il2r
GenBank蛋白编号BC114437
基因名称 CD25
Gene ID (NCBI) 16184
RRIDAB_2883198
偶联类型 CoraLite® Plus 488 Fluorescent Dye
最大激发/发射波长493 nm / 522 nm
形式 Liquid
纯化方式Affinity purification
UNIPROT IDP01590
储存缓冲液 PBS with 0.1% sodium azide and 0.5% BSA, pH 7.3.
储存条件Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment.

背景介绍

Proliferation of T lymphocytes is triggered by the interaction of IL-2 with its specific receptor following T lymphocyte activation. The receptor for IL-2 has three forms, generated by different combinations of three different proteins, the alpha chain (IL-2R alpha), the beta chain (IL-2R beta), and the gamma chain (IL-2R gamma) (PMID: 8476561). IL-2R alpha (also known as CD25) is a type I transmembrane protein present on activated T cells, activated B cells, some thymocytes, myeloid precursors, and oligodendrocytes. CD25 is also found on natural CD4+Foxp3+ Treg cells (PMID: 22585674).

实验方案

Product Specific Protocols
FC protocol for CL Plus 488 CD25/IL-2RA antibody CL488-65137Download protocol
Standard Protocols
Click here to view our Standard Protocols
Loading...